Sanofi (SNYNF) is scheduled to report 3rd quarter earnings on 10/27/2023, before the market opens.
Regarding Q3 estimates, Wall Street analysts expect Sanofi to post earnings of €2.60 per share. Revenue expectations are pegged at €12.47 billion. Last quarter, Sanofi beat earnings estimates, reporting EPS of €1.74 on estimates of €1.68. The stock fell by -1.92% the day after the last earnings release.
Year-to-date, SNYNF stock has risen by 5.77%.
Is Sanofi Stock a Buy?
Wall Street’s consensus rating for SNYNF stock is a Moderate Buy, with an average analyst price target of $112.77, implying upside potential of 8.96% from current levels.
SNYNF shares have lost about -8.41% in the past six months.
About Sanofi
Sanofi engages in the research, production and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Human Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes & cardiovascular, established prescription products and generics, together with research, development and production activities. This segment also includes all associates whose activities are related to pharmaceuticals. The Consumer Healthcare segment comprises, for all geographical territories, the commercial operations for its Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development and production activities dedicated to vaccines. The company was founded in 1973 and is headquartered in Paris, France.
Stay up-to-date on earnings this week, with TipRanks’ Earnings Calendar.
